PAA
WST icon

Peregrine Asset Advisers’s West Pharmaceutical WST Stock Holding History

Peregrine Asset Advisers’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-800
Closed -$375K – 148
2021
Q4 		$375K Sell
800
-100
-11% -$43K 0.15% 86
2021
Q3 		$382K Buy
900
+100
+13% +$42.2K 0.2% 78
2021
Q2 		$287K Sell
800
-53
-6% -$17.5K 0.13% 95
2021
Q1 		$240K Hold
853
– – 0.12% 96
2020
Q4 		$242K Hold
853
– – 0.11% 107
2020
Q3 		$234K Buy
+853
New +$226K 0.13% 88

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Peregrine Asset Advisers's WST Position: Q1 2022 in Review

Peregrine Asset Advisers sold out of West Pharmaceutical (WST) in Q1 2022, closing a stake of 800 shares — an estimated $375K sold.

Peregrine Asset Advisers first reported a position in WST in Q3 2020 and held it in 6 quarters. The position peaked at $382K in Q3 2021. 716 funds tracked by Wall St. Rank hold WST as of Q1 2022.

  • Peregrine Asset Advisers reported no remaining West Pharmaceutical position as of Q1 2022 after selling out during the quarter.
  • Peregrine Asset Advisers sold 800 West Pharmaceutical shares in Q1 2022, an estimated $375K.
  • Peregrine Asset Advisers first reported a position in West Pharmaceutical in Q3 2020 and held it in 6 quarters.
  • Peregrine Asset Advisers's West Pharmaceutical position peaked at $382K in Q3 2021.
  • 716 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2022.

Based on Peregrine Asset Advisers's 13F filing for Q1 2022, filed 5 May 2022.